Cote d'Ivoire vs Japan: The number of people with susceptibility test result for rifampicin
Cote d'Ivoire
59.19
in 2021
Japan
62.2
in 2021
Cote d'Ivoire rank
111th
Japan rank
108th
The number of people with susceptibility test result for rifampicin over time
- Cote d'Ivoire
- Japan
How they compare
Japan currently reports 62.2 against 59.19 in Cote d'Ivoire, a difference of 3.01.
That makes Japan's figure about 1.1 times Cote d'Ivoire's.
Across all 5 years both countries report, Japan has been ahead every year.
Cote d'Ivoire ranks 111th and Japan ranks 108th of 146 countries.
Japan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cote d'Ivoire | Japan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 23.43 | 71.84 | 48.41 | Japan |
| 2020s | 34.58 | 63.07 | 28.49 | Japan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Cote d'Ivoire or Japan?
- Japan, at 62.2 against 59.19 in Cote d'Ivoire as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Cote d'Ivoire and Japan?
- 3.01, with Japan ahead.
- How many years of comparable data are there for Cote d'Ivoire and Japan?
- 5 years are reported by both, from 2017 to 2021.
- How do Cote d'Ivoire and Japan rank globally for the number of people with susceptibility test result for rifampicin?
- Cote d'Ivoire ranks 111th and Japan ranks 108th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.